Major Randomized Clinical Trials in Cardiovascular Disease Prevention Presented at the 2019 American College of Cardiology Annual Scientific Session-Reference-Cited by-同舟云学术

Major Randomized Clinical Trials in Cardiovascular Disease Prevention Presented at the 2019 American College of Cardiology Annual Scientific Session

Published:2019-05-24 Issue:8 Volume:21 Page:
ISSN:1523-3804
Container-title:Current Atherosclerosis Reports
language:en
Short-container-title:Curr Atheroscler Rep

Author:

Al Rifai Mahmoud,Jia Xiaoming,Al-Mallah Mouaz H.,Miedema Michael D.,Martin Seth S.,Virani Salim S.

Publisher

Springer Science and Business Media LLC

Subject

Cardiology and Cardiovascular Medicine

Link

http://link.springer.com/content/pdf/10.1007/s11883-019-0789-3.pdf

Reference18 articles.

1. •• Goldberg A. Efficacy and Safety of Bempedoic Acid Added to Maximally Tolerated Statins in Patients with Hypercholesterolemia and High Cardiovascular Risk: The CLEAR Wisdom Trial. Am Coll Cardiol Annu Sci Sess (ACC 2019) New Orleans, LA. This study demonsrates the efficacy and safety of bempedoic acid for LDL-C lowring in high risk patients as compared to maximally tolerated statin.

2. Jia X, Virani SS. CLEAR serenity trial: more clarity for the future of Bempedoic acid in patients unable to take statins? J Am Heart Assoc. 2019;8:e012352.

3. • Bhatt DL, Steg PG, Miller M, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med. 2019;380:11–22 This is the first study to show the efficacy of icosapent ethyl for reducing cardiovacular events in secondary prevention or high-risk primary prevention patients with type 2 diabetes mellitus with elevated triglycerides and relatively well-controlled LDL-C.

4. •• Bhatt DL, Steg PG, Miller M, et al. Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT. J Am Coll Cardiol. 2019; published online March. https://doi.org/10.1016/j.jacc.2019.02.032 . This study is a post-hoc analysis of the REDUCE-IT trial demonstrating the efficacy of icosapent ethyl for reducing risk of total (first and subsequent) cardiovacular events.

5. Musunuru K, Kathiresan S. Surprises from genetic analyses of lipid risk factors for atherosclerosis. Circ Res. 2016;118:579–85.

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Highlights of Cardiovascular Disease Studies Presented at the 2021 European Society of Cardiology Congress;Current Atherosclerosis Reports;2021-10-14

2. Highlights from Studies Presented at the American Heart Association Scientific Session 2020: Navigating New Roads in Prevention;Current Atherosclerosis Reports;2021-01

3. Major inducing factors of hypertensive complications and the interventions required to reduce their prevalence: a review;International Journal of Medicine in Developing Countries;2021

4. Highlights from Studies in Cardiovascular Disease Prevention Presented at the Digital 2020 European Society of Cardiology Congress: Prevention Is Alive and Well;Current Atherosclerosis Reports;2020-10-03

5. Highlights of Studies in Cardiovascular Disease Prevention Presented at the 2020 American College of Cardiology Annual Scientific Session;Current Atherosclerosis Reports;2020-06-18